OIG Pharma Guidance: The Impact on CME

In April, the Office of Inspector General released its Final Compliance Program Guidance for Pharmaceutical Manufacturers, designed to help drug and device firms comply with federal antikickback laws and other fraud and abuse statutes. One of the areas the guidance addresses is education grants, and there are major implications for firms’ relationships with continuing medical education (CME) providers.

Register to view the full article

Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.